Correspondence

Decision on Evusheld as a coronavirus (COVID-19) treatment: letter to patient groups

The Secretary of State for Health and Social Care's letter to a group of charities and patients on the decision not to procure Evusheld as a COVID-19 treatment.

From:
Department of Health and Social Care and The Rt Hon Steve Barclay MP
Published
6 October 2022

Documents

Decision on Evusheld as a COVID-19 treatment

HTML

Details

This letter from the Rt Hon Steve Barclay MP, then Secretary of State for Health and Social Care, was sent to a group of charities and patient groups on 5 September 2022.

It gives an overview of the:

  • information that was used in the decision by the UK government not to procure Evusheld (tixagevimab plus cilgavimab) as a pre-exposure prophylaxis used in the treatment of COVID-19
  • expert advice provided by the research to access pathway for investigational drugs for COVID-19 (RAPID C-19) Oversight Group, and the limitations of the data available
  • next steps the government is considering

This correspondence has been published alongside the RAPID C-19 Oversight Group’s independent review of the efficacy of Evusheld.

Published 6 October 2022

Related content